NCT06758700
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Recruiting · Phase 2 · Shanghai Pulmonary Hospital, Shanghai, China · registry updated 2025-12-05
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
Inclusion
- extensive stage small cell lung cancer
- Progression after receiving at least one chemotherapy drug treatment in the past;
- ECOG score 0-1
- c-Myc-driven
- Expected survival period ≥3 months
- Age: 18-75 years old;
Exclusion
- No measurable lesions
- Other severe and persistent diseases or organ system dysfunction;
- Women planning pregnancy or men planning family planning;
- Women who are pregnant or breastfeeding;
- Those who cannot follow the research protocol provided by the investigator.